Clinic
UPMC East
UPMC East was paid $5.77M by Medicaid between Jan 2018 and Dec 2024, across 177 billing codes. Its largest line is 99284, emergency room visit (serious) — 41% of everything it billed.
33Billing provider infoUPMC EAST
MONROEVILLE, PA 15146
MONROEVILLE, PA 15146
33aNPI1225323983assigned 06/10/2011
33bProvider typeClinic/Center
28Total paid$5.77M
24GClaims206,869
24DCodes billed177
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinic/Center providers in Pennsylvania
Rank by total paid#28 of 176
Median peer was paid$441K
This provider vs. median13×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 68 | $3K | |
| 2019 | 128 | $4K | |
| 2020 | 17,595 | $421K | |
| 2021 | 80,301 | $2.23M | |
| 2022 | 36,825 | $969K | |
| 2023 | 39,069 | $1.15M | |
| 2024incomplete | 32,883 | $997K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 41% | 16,079 | 15,667 | $2.39M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 13% | 4,777 | 4,638 | $759K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 9.5% | 5,859 | 5,716 | $549K |
| G0378 | Hospital observation service, per hour | 6.8% | 2,042 | 892 | $391K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 6.4% | 1,324 | 1,298 | $371K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.7% | 8,306 | 8,029 | $154K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.1% | 1,006 | 981 | $123K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 1.5% | 259 | 253 | $86K |
| 80053 | Comprehensive metabolic panel | 1.3% | 9,640 | 9,153 | $73K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.3% | 18,951 | 17,294 | $73K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.1% | 9,214 | 8,812 | $63K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,640 | 3,341 | $46K |
165 more codes
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 308 | $42K |
| 84484 | <1% | 5,327 | $37K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 840 | $34K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 6,036 | $33K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,891 | $30K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 542 | $30K |
| 64415 | <1% | 105 | $26K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 505 | $26K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,161 | $25K |
| 84703 | <1% | 3,408 | $23K | |
| J3490 | Unclassified drugs | <1% | 6,603 | $21K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 333 | $19K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 161 | $19K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 294 | $16K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 418 | $15K |
| 93971 | <1% | 283 | $14K | |
| 83690 | <1% | 4,110 | $13K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 102 | $13K |
| 64721 | <1% | 54 | $12K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 203 | $11K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 241 | $10K |
| T1015 | A visit at a community health center or clinic (one all-in rate) | <1% | 472 | $10K |
| 80050 | General health panel | <1% | 247 | $10K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 344 | $9K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,938 | $9K |
| 82805 | <1% | 422 | $9K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 245 | $8K |
| 81001 | <1% | 4,002 | $8K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 180 | $7K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 20 | $7K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 16 | $6K |
| 83880 | <1% | 307 | $6K | |
| 83735 | <1% | 1,354 | $6K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 322 | $5K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,586 | $5K |
| 85610 | <1% | 2,227 | $5K | |
| 85730 | <1% | 1,179 | $5K | |
| 93017 | <1% | 213 | $5K | |
| 83605 | <1% | 885 | $4K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 156 | $4K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 580 | $4K |
| 62323 | <1% | 16 | $4K | |
| 80061 | Lipid panel | <1% | 335 | $4K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 782 | $4K |
| 80076 | <1% | 665 | $3K | |
| 85379 | <1% | 448 | $3K | |
| 88342 | <1% | 169 | $3K | |
| 87040 | <1% | 324 | $3K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 210 | $3K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 210 | $3K |
| 70496 | <1% | 26 | $3K | |
| J1815 | Injection, insulin, per 5 units | <1% | 393 | $3K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 18 | $3K |
| 73610 | <1% | 199 | $2K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 238 | $2K |
| 93970 | <1% | 28 | $2K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 86 | $2K |
| 84100 | <1% | 524 | $2K | |
| 72100 | <1% | 124 | $2K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 4,648 | $2K |
| 73630 | <1% | 273 | $2K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 336 | $2K |
| 81003 | <1% | 791 | $2K | |
| 73030 | <1% | 137 | $1K | |
| 73130 | <1% | 173 | $1K | |
| 85027 | <1% | 426 | $1K | |
| 82607 | <1% | 164 | $1K | |
| 82962 | <1% | 1,425 | $1K | |
| 84702 | <1% | 94 | $1K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,668 | $1K |
| 70498 | <1% | 14 | $1K | |
| 76937 | <1% | 231 | $1K | |
| 86850 | <1% | 230 | $984.94 | |
| 71250 | <1% | 24 | $891.31 | |
| 90715 | <1% | 198 | $798.53 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 4,793 | $794.84 |
| 97162 | <1% | 60 | $785.78 | |
| 87077 | <1% | 170 | $782.63 | |
| 82728 | <1% | 84 | $769.92 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 19 | $752.80 |
| 84439 | <1% | 116 | $715.87 | |
| 87480 | <1% | 55 | $706.57 | |
| 87660 | <1% | 55 | $679.38 | |
| 86140 | <1% | 319 | $667.59 | |
| 85651 | <1% | 310 | $634.37 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 4,794 | $585.37 |
| 82565 | <1% | 158 | $556.82 | |
| 94726 | <1% | 27 | $553.31 | |
| 82746 | <1% | 82 | $552.00 | |
| 83540 | <1% | 98 | $549.59 | |
| 73562 | <1% | 62 | $527.09 | |
| 87186 | <1% | 119 | $524.40 | |
| 86901 | <1% | 238 | $514.77 | |
| 86900 | <1% | 238 | $508.17 | |
| J8501 | Aprepitant, oral, 5 mg | <1% | 114 | $499.07 |
| 73560 | <1% | 60 | $498.56 | |
| 76942 | <1% | 253 | $479.05 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,561 | $427.62 |
| 70486 | <1% | 12 | $426.25 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 8,596 | $405.53 |
| 77336 | <1% | 20 | $402.52 | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 44 | $361.79 |
| Q9950 | Injection, sulfur hexafluoride lipid microspheres, per ml | <1% | 14 | $335.70 |
| 94729 | <1% | 15 | $333.84 | |
| 83550 | <1% | 90 | $308.55 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,661 | $254.80 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 576 | $248.49 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,087 | $243.97 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,048 | $238.91 |
| 82550 | <1% | 49 | $226.94 | |
| 97166 | <1% | 13 | $203.70 | |
| 88341 | <1% | 27 | $179.89 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,585 | $179.89 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 436 | $174.85 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 204 | $143.53 |
| 84134 | <1% | 12 | $120.85 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 436 | $113.02 |
| 73590 | <1% | 13 | $108.08 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,332 | $102.87 |
| 94060 | <1% | 14 | $101.23 | |
| J2704 | Injection, propofol, 10 mg | <1% | 2,840 | $95.48 |
| 87070 | <1% | 27 | $91.08 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,995 | $87.16 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 27 | $76.23 |
| 97161 | <1% | 26 | $69.97 | |
| 80329 | <1% | 13 | $65.31 | |
| 80051 | <1% | 12 | $53.90 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 273 | $51.81 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 12 | $47.43 |
| 84520 | <1% | 13 | $47.30 | |
| 96376 | <1% | 227 | $38.69 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 228 | $38.39 |
| 73110 | <1% | 12 | $37.95 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 232 | $23.11 |
| 87081 | <1% | 12 | $22.62 | |
| J7999 | Compounded drug, not otherwise classified | <1% | 1,384 | $20.92 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 70 | $18.84 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 734 | $16.89 |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 134 | $15.00 |
| 88304 | <1% | 49 | $14.30 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 35 | $13.44 |
| 36415 | Collection of venous blood by venipuncture | <1% | 431 | $8.28 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 594 | $7.16 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 368 | $5.34 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 1,249 | $4.00 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 36 | $3.71 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 102 | $1.53 |
| Q0243 | Injection, casirivimab and imdevimab, 2400 mg | <1% | 19 | $0.04 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 164 | $0.00 |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | 0% | 52 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 275 | $0.00 |
| J0137 | Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg | 0% | 60 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 102 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 130 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 28 | $0.00 |
| S0028 | Injection, famotidine, 20 mg | 0% | 100 | $0.00 |
| J3535 | Drug administered through a metered dose inhaler | 0% | 13 | $0.00 |
| C1889 | Implantable/insertable device, not otherwise classified | 0% | 66 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 28 | $0.00 |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | 0% | 75 | $0.00 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 53 | $0.00 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 75 | $0.00 |
| C1769 | Guide wire | 0% | 12 | $0.00 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 13 | $0.00 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 0% | 56 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTIMMONS, LAURENE (CFO)
Parent organizationUPMC
| Provider | Location | Paid |
|---|---|---|
| UPMC Mckeesport | Mckeesport, PA | $9.96M |
| UPMC Mckeesport | Mckeesport, PA | $34.43 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.